Early-stage therapeutic efficacy of TNAP inhibition using a novel milder murine model of CKD-MBD

Area of Science:

• Nephrology
• Biochemistry
• Pharmacology

Background:

• Chronic kidney disease (CKD) is a complex systemic illness with mineral bone disorder (CKD-MBD) as a key feature.
• Early intervention for CKD-MBD is crucial but limited by multifactorial pathophysiology and inadequate animal models.
• Tissue nonspecific alkaline phosphatase (TNAP) plays a role in mineral metabolism, making it a potential therapeutic target.

Purpose of the Study:

• To evaluate the efficacy of the TNAP inhibitor SBI-425 in a novel animal model of CKD-MBD.
• To assess the impact of SBI-425 on renal damage, ectopic calcification, and key biochemical markers associated with CKD-MBD.

Main Methods:

• A CKD-MBD animal model was established using nephrectomy and a high inorganic phosphate diet, inducing renal damage and elevated BUN.
• Animals received oral administration of SBI-425 (1 and 10 mg/kg) twice daily for 12 weeks.
• Evaluated renal tubule calcification, plasma levels of fibroblast growth factor 23 (FGF-23), parathyroid hormone (PTH), phosphate, and BUN.

Main Results:

• SBI-425 treatment significantly inhibited the progression of calcium deposition in renal tubules.
• The drug effectively prevented the deterioration of plasma BUN, FGF-23, PTH, and phosphate levels.
• The model successfully replicated key pathophysiological features of CKD-MBD, including renal damage and ectopic calcification.

Conclusions:

• TNAP inhibition with SBI-425 demonstrates significant potential in slowing CKD-MBD progression.
• Inhibiting TNAP effectively reduces renal tubule calcification and stabilizes critical biochemical markers.
• These findings suggest TNAP inhibitors could offer a new therapeutic strategy for managing CKD-MBD in patients.